Abstract:Background: The knowledge that persistent human papillomavirus (HPV) infection is the main cause of cervical cancer has resulted in the development of prophylactic vaccines to prevent HPV infection and HPV assays that detect nucleic acids of the virus. WHO has launched a Global Initiative to scale up preventive, screening, and treatment interventions to eliminate cervical cancer as a public health problem during the 21st century. Therefore, our study aimed to assess the existing burden of cervical cancer as a baseline from which to assess the effect of this initiative. Methods: For this worldwide analysis, we used data of cancer estimates from 185 countries from the Global Cancer Observatory 2018 database. We used a hierarchy of methods dependent on the availability and quality of the source information from population-based cancer registries to estimate incidence of cervical cancer. For estimation of cervical cancer mortality, we used the WHO mortality database. Countries were grouped in 21 subcontinents and were also categorised as high-resource or lower-resource countries, on the basis of their Human Development Index. We calculated the number of cervical cancer cases and deaths in a given country, directly age-standardised incidence and mortality rate of cervical cancer, indirectly standardised incidence ratio and mortality ratio, cumulative incidence and mortality rate, and average age at diagnosis. Findings: Approximately 570 000 cases of cervical cancer and 311 000 deaths from the disease occurred in 2018. Cervical cancer was the fourth most common cancer in women, ranking after breast cancer (2·1 million cases), colorectal cancer (0·8 million) and lung cancer (0·7 million). The estimated age-standardised incidence of cervical cancer was 13·1 per 100 000 women globally and varied widely among countries, with rates ranging from less than 2 to 75 per 100 000 women. Cervical cancer was the leading cause of cancer-related death in women in eastern, western, middle, and southern Africa. The highest incidence was estimated in Eswatini, with approximately 6·5% of women developing cervical cancer before age 75 years. China and India together contributed more than a third of the global cervical burden, with 106 000 cases in China and 97 000 cases in India, and 48 000 deaths in China and 60 000 deaths in India. Globally, the average age at diagnosis of cervical cancer was 53 years, ranging from 44 years (Vanuatu) to 68 years (Singapore). The global average age at death from cervical cancer was 59 years, ranging from 45 years (Vanuatu) to 76 years (Martinique). Cervical cancer ranked in the top three cancers affecting women younger than 45 years in 146 (79%) of 185 countries assessed. Interpretation: Cervical cancer continues to be a major public health problem affecting middle-aged women, particularly in less-resourced countries. The global scale-up of HPV vaccination and HPV-based screening-including self-sampling-has potential to make cervical cancer a rare disease in the decades to come. Our study could help shape and monitor the initiative to eliminate cervical cancer as a major public health problem. Funding: Belgian Foundation Against Cancer, DG Research and Innovation of the European Commission, and The Bill & Melinda Gates Foundation.

Worldwide trend in human papillomavirus–attributable cancer incidence rates between 1990 and 2012 and Bayesian projection to 2030

Prevalence and Genotype Distribution of Human Papillomavirus Among Healthy Females in Beijing, China, 2016-2019

Analysis of Epidemiological Trends in Human Papillomavirus Infection among Gynaecological Outpatients in Hangzhou, China, 2011–2015

Cancer Attributable to Human Papillomavirus Infection in China: Burden and Trends

Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators

Prevalence of High-Risk Human Papillomavirus and Cervical Lesion Risk Factors: A Population-Based Study in Zhejiang, China 2010-2019

Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

Prevalence and genotype distribution of human papillomavirus infection among 66000 women from 2014 to 2023 in the plateau region of Southwest China

Global Burden of Oropharyngeal Cancer Attributable to Human Papillomavirus by Anatomical Subsite and Geographic Region.

Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years

Human Papillomaviruses Genotype Distribution and Replacement by Year from 2014 to 2020 in Beijing, China

Worldwide burden of cancer attributable to HPV by site, country and HPV type

Trend of HPV Molecular Epidemiology in the Post-Vaccine Era: A 10-Year Study

Modelling suggests that high human papilloma virus (HPV) vaccination coverage in combination with high uptake screening can lead to cervical cancer elimination in most low-income and lower-middle-income countries (LMICs) by the end of the century

Prevalence and Distribution of Human Papillomavirus Genotypes in Chinese Women Between 1991 and 2016: A Systematic Review

Navigating the landscape of HPV-associated cancers: From epidemiology to prevention

Human Papilloma Virus Infection and Gene Subtypes Analysis in Women Undergoing Physical Examinations: A 2015-2020 Study in Wenzhou, China

Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis

Epidemiology of human papillomavirus infection in women from Xiamen, China, 2013 to 2023

Epidemiology of cervical cancer and HPV infection in Asia and Oceania

Changes in the Incidence and Human Papillomavirus-Positive Portion of Oropharyngeal Squamous Cell Carcinoma in Hong Kong